Pharsight

Drug Patents Expiring in 2026

1. Abilify patents expiration

ABILIFY's oppositions filed in EPO
ABILIFY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Aug 27, 2011
Orphan Drug Exclusivity(ODE) Dec 12, 2021
M(M-137) Jun 09, 2017
New Indication(I-700) Dec 12, 2017
Orphan Drug Exclusivity(ODE-80) Dec 12, 2021
New Indication(I-633) Feb 16, 2014

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 07 June, 2006

Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL; TABLET;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

2. Abilify Mycite Kit patents expiration

ABILIFY MYCITE KIT's oppositions filed in EPO
ABILIFY MYCITE KIT Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11476952 OTSUKA Pharma-informatics system
Apr, 2026

(2 years from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US7978064 OTSUKA Communication system with partial power source
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-150) Dec 05, 2017
New Indication(I-746) Jul 27, 2020

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

Family Patents

3. Abraxane patents expiration

ABRAXANE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7758891 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 10 months from now)

US8268348 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 10 months from now)

US9101543 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2026

(1 year, 10 months from now)

US8034375 BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US9101543

(Pediatric)

BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US8268348

(Pediatric)

BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

US7758891

(Pediatric)

BRISTOL-MYERS Combinations and modes of administration of therapeutic agents and combination therapy
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 06, 2023
M(M-14) Dec 06, 2022
New Indication(I-676) Sep 06, 2016
Orphan Drug Exclusivity(ODE) Sep 06, 2020
Orphan Drug Exclusivity(ODE-52) Sep 06, 2020
New Indication(I-658) Oct 11, 2015

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of pancreatic cancer; Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage

ABRAXANE family patents

Family Patents

4. Acetadote patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor
May, 2026

(2 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

5. Actoplus Met Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7959946 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

US7785627 TAKEDA PHARMS USA Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Jul, 2026

(2 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 12 May, 2009

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ACTOPLUS MET XR before it's drug patent expiration?
More Information on Dosage

ACTOPLUS MET XR family patents

Family Patents

6. Adasuve patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8387612 ALEXZA PHARMS Self-contained heating unit and drug-supply unit employing same
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Dec 21, 2015

Drugs and Companies using LOXAPINE ingredient

Market Authorisation Date: 21 December, 2012

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ADASUVE family patents

Family Patents

7. Adempas patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 08, 2020
New Chemical Entity Exclusivity(NCE) Oct 08, 2018
Orphan Drug Exclusivity(ODE-53) Oct 08, 2020

Drugs and Companies using RIOCIGUAT ingredient

NCE-1 date: 08 October, 2017

Market Authorisation Date: 08 October, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ADEMPAS before it's drug patent expiration?
More Information on Dosage

ADEMPAS family patents

Family Patents

8. Advair Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Feb, 2026

(1 year, 10 months from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Aug, 2026

(2 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 08 June, 2006

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ADVAIR HFA family patents

Family Patents

9. Adzenys Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840924 NEOS THERAPS Compositions and methods of making rapidly dissolving ionically masked formulations
Apr, 2026

(1 year, 11 months from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of ADZENYS XR-ODT before it's drug patent expiration?
More Information on Dosage

ADZENYS XR-ODT family patents

Family Patents

10. Afinitor patents expiration

Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131

(Pediatric)

NOVARTIS Cancer treatment
May, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-724) Feb 26, 2019
Orphan Drug Exclusivity(ODE-108) Feb 26, 2023
Orphan Drug Exclusivity(ODE-24) Apr 26, 2019
Orphan Drug Exclusivity(ODE-11) May 05, 2018
New Chemical Entity Exclusivity(NCE) Mar 30, 2014
New Indication(I-630) Oct 29, 2013
New Indication(I-655) Jul 20, 2015
New Indication(I-650) Apr 26, 2015
Orphan Drug Exclusivity(ODE) Apr 26, 2019
Pediatric Exclusivity(PED) Oct 26, 2015
New Indication(I-638) May 05, 2014

Drugs and Companies using EVEROLIMUS ingredient

NCE-1 date: 26 October, 2014

Market Authorisation Date: 09 July, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage

AFINITOR family patents

Family Patents

11. Afrezza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7943572 MANNKIND Superior control of blood glucose in diabetes treatment
Aug, 2026

(2 years from now)

US9283193 MANNKIND Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
Sep, 2026

(2 years from now)

US9717689 MANNKIND Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 27, 2017

Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient

Market Authorisation Date: 27 June, 2014

Treatment: Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin.

Dosage: POWDER;INHALATION

More Information on Dosage

AFREZZA family patents

Family Patents

12. Akten patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759401 THEA PHARMA Aqueous gel formulation and method for inducing topical anesthesia
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 07, 2011

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 October, 2008

Treatment: Method of inducing topical anesthesia in the eye

Dosage: GEL;OPHTHALMIC

More Information on Dosage

AKTEN family patents

Family Patents

13. Amondys 45 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8524880 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Apr, 2026

(1 year, 11 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-347) Feb 25, 2028
New Chemical Entity Exclusivity(NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: 25 February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by inducing exon-skipping of exon 45

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMONDYS 45 family patents

Family Patents

14. Ampyra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354437 ACORDA Method of using sustained release aminopyridine compositions
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jan 22, 2017
New Chemical Entity Exclusivity(NCE) Jan 22, 2015

Drugs and Companies using DALFAMPRIDINE ingredient

NCE-1 date: 22 January, 2014

Market Authorisation Date: 22 January, 2010

Treatment: Improvement of walking in patients with multiple sclerosis (ms)

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage

AMPYRA family patents

Family Patents

15. Androgel patents expiration

ANDROGEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8729057 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8754070 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8486925 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466138 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466136 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8466137 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8759329 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8741881 BESINS HLTHCARE Testosterone gel and method of use
Oct, 2026

(2 years from now)

US8446138 BESINS HLTHCARE Stability compensation circuit and DC-DC converter including the same
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 29, 2014

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 29 April, 2011

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL;TRANSDERMAL; GEL, METERED;TRANSDERMAL

More Information on Dosage

ANDROGEL family patents

Family Patents

16. Aplenzin patents expiration

Can you believe APLENZIN received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7585897 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(2 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(2 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7569610 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

Drugs and Companies using BUPROPION HYDROBROMIDE ingredient

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of APLENZIN before it's drug patent expiration?
More Information on Dosage

APLENZIN family patents

Family Patents

17. Apretude patents expiration

APRETUDE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(2 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026

Drugs and Companies using CABOTEGRAVIR ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 20 December, 2021

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

APRETUDE family patents

Family Patents

18. Aptiom patents expiration

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9206135 SUMITOMO PHARMA AM Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9643929 SUMITOMO PHARMA AM Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-150) Aug 27, 2018
New Indication(I-715) Aug 27, 2018
New Chemical Entity Exclusivity(NCE) Nov 08, 2018

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

NCE-1 date: 08 November, 2017

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage

APTIOM family patents

Family Patents

19. Aricept patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481565 EISAI INC Method for stabilizing anti-dementia drug
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 23, 2013

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ARICEPT before it's drug patent expiration?
More Information on Dosage

ARICEPT family patents

Family Patents

20. Arikayce Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8632804 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

US8679532 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

US8642075 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-214) Sep 28, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults with cystic fibrosis as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part ...

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

ARIKAYCE KIT family patents

Family Patents

21. Atelvia patents expiration

ATELVIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246989 APIL Dosage forms of bisphosphonates
Jan, 2026

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Oct 08, 2013

Drugs and Companies using RISEDRONATE SODIUM ingredient

Market Authorisation Date: 08 October, 2010

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of ATELVIA before it's drug patent expiration?
More Information on Dosage

ATELVIA family patents

Family Patents

22. Atripla patents expiration

ATRIPLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form
Jun, 2026

(2 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in pediatric patients 12 years of age and older

Dosage: TABLET;ORAL

How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage

ATRIPLA family patents

Family Patents

23. Aubagio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-61) Apr 30, 2024
Pediatric Exclusivity(PED) Oct 30, 2024
New Chemical Entity Exclusivity(NCE) Sep 12, 2017

Drugs and Companies using TERIFLUNOMIDE ingredient

NCE-1 date: 31 October, 2023

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage

AUBAGIO family patents

Family Patents

24. Auryxia patents expiration

AURYXIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8093423 KERYX BIOPHARMS Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
Apr, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-790) Nov 06, 2020

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorous levels

Dosage: TABLET;ORAL

More Information on Dosage

AURYXIA family patents

Family Patents

25. Auvi-q patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2026

(1 year, 9 months from now)

US9259539 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2026

(1 year, 9 months from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2026

(1 year, 11 months from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US11590286 KALEO INC Devices, systems and methods for medicament delivery
Dec, 2026

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 17 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

Family Patents

26. Avycaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7112592 ALLERGAN Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Jan, 2026

(1 year, 8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7612087 ALLERGAN Heterocyclic compounds as inhibitors of beta-lactamases
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2020
New Patient Population(NPP) Dec 20, 2025
Generating Antibiotic Incentives Now(GAIN) Feb 25, 2025
New Indication(I-738) Jun 22, 2019

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: 26 February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

AVYCAZ family patents

Family Patents

27. Axiron patents expiration

AXIRON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8993520 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(2 years from now)

US9180194 ELI LILLY AND CO Method and composition for transdermal drug delivery
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 23, 2013

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's drug patent expiration?
More Information on Dosage

AXIRON family patents

Family Patents

28. Axumin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387266 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10953112 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

US10010632 BLUE EARTH Precursor compound of radioactive halogen-labeled organic compound
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Method of diagnosing tumors using positron emission tomography

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AXUMIN family patents

Family Patents

29. Azilect patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 TEVA Rasagiline formulations and processes for their preparation
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-685) May 29, 2017

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

AZILECT family patents

Family Patents

30. Baxdela patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027
New Indication(I-815) Oct 24, 2022

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: TABLET;ORAL; POWDER;INTRAVENOUS

More Information on Dosage

BAXDELA family patents

Family Patents

31. Beleodaq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6888027 ACROTECH BIOPHARMA Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jul 03, 2021
New Chemical Entity Exclusivity(NCE) Jul 03, 2019
Orphan Drug Exclusivity(ODE-68) Jul 03, 2021

Drugs and Companies using BELINOSTAT ingredient

NCE-1 date: 03 July, 2018

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage

BELEODAQ family patents

Family Patents

32. Belrapzo patents expiration

BELRAPZO's oppositions filed in EPO
BELRAPZO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage

BELRAPZO family patents

Family Patents

33. Bendeka patents expiration

BENDEKA's oppositions filed in EPO
BENDEKA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 8 months from now)

US8791270

(Pediatric)

EAGLE PHARMS Bendamustine pharmaceutical compositions
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179) Dec 07, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

34. Bevyxxa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7598276 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9555023 PORTOLA PHARMS INC Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: 23 June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: Prophylaxis of pulmonary embolism

Dosage: CAPSULE;ORAL

More Information on Dosage

BEVYXXA family patents

Family Patents

35. Bosulif patents expiration

BOSULIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7417148

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(2 years from now)

US7919625

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030
New Indication(I-923) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Chemical Entity Exclusivity(NCE) Sep 04, 2017

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: NA

Dosage: TABLET;ORAL; CAPSULE;ORAL

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

36. Bridion patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE44733 MSD SUB MERCK 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block
Jan, 2026

(1 year, 9 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 25, 2024
M(M-291) Jan 22, 2024
New Chemical Entity Exclusivity(NCE) Dec 15, 2020
M(M-262) Jun 09, 2023

Drugs and Companies using SUGAMMADEX SODIUM ingredient

NCE-1 date: 16 December, 2019

Market Authorisation Date: 15 December, 2015

Treatment: Reversal of drug-induced neuromuscular block

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage

BRIDION family patents

Family Patents

37. Brisdelle patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8946251 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393237 SEBELA IRELAND LTD Method of treating thermoregulatory dysfunction with paroxetine
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 28, 2016

Drugs and Companies using PAROXETINE MESYLATE ingredient

Market Authorisation Date: 28 June, 2013

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: CAPSULE;ORAL

How can I launch a generic of BRISDELLE before it's drug patent expiration?
More Information on Dosage

BRISDELLE family patents

Family Patents

38. Briviact patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6911461 UCB INC 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Feb, 2026

(1 year, 10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 27, 2024
New Chemical Entity Exclusivity(NCE) May 12, 2021

Drugs and Companies using BRIVARACETAM ingredient

NCE-1 date: 12 May, 2020

Market Authorisation Date: 12 May, 2016

Treatment: Treatment of partial-onset seizures in patients 4 years of age and older

Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS; SOLUTION;ORAL

How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage

BRIVIACT family patents

Family Patents

39. Brixadi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8236755 BRAEBURN Opioid depot formulations
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2026

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 23 May, 2023

Treatment: A method of delivery of an opioid bioactive agent. a method of treatment or prophylaxis of a human or non-human animal for the treatment of opioid addiction and/or the symptoms of opioid withdrawal

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BRIXADI family patents

Family Patents

40. Bydureon patents expiration

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 11 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic con...

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

41. Bydureon Bcise patents expiration

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 11 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025
M(M-240) Feb 15, 2022
New Product(NP) Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet ...

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

42. Bydureon Pen patents expiration

BYDUREON PEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 11 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

43. Byvalson patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803838 ABBVIE Compositions comprising nebivolol
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jun 03, 2019

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's drug patent expiration?
More Information on Dosage

BYVALSON family patents

Family Patents

44. Cabenuva Kit patents expiration

CABENUVA KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8410103 VIIV HLTHCARE (3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Apr, 2026

(2 years from now)

US10927129 VIIV HLTHCARE N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Apr, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2026
New Patient Population(NPP) Mar 29, 2025
New Dosing Schedule(D-184) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 21 January, 2025

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

Family Patents

45. Cabometyx patents expiration

Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579473 EXELIXIS INC c-Met modulators and methods of use
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-227) Jan 14, 2026
New Indication(I-854) Jan 22, 2024
Orphan Drug Exclusivity(ODE-375) Sep 17, 2028
New Indication(I-873) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Nov 29, 2017
New Indication(I-760) Dec 19, 2020
New Product(NP) Apr 25, 2019
New Indication(I-792) Jan 14, 2022

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage

CABOMETYX family patents

Family Patents

46. Calquence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents

47. Calquence patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026
New Indication(I-817) Nov 21, 2022
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

48. Cambia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7759394 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US8097651 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9827197 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

US8927604 ASSERTIO Diclofenac formulations and methods of use
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jun 17, 2012

Drugs and Companies using DICLOFENAC POTASSIUM ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Acute treatment of migraine attacks with or without aura in adults

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of CAMBIA before it's drug patent expiration?
More Information on Dosage

CAMBIA family patents

Family Patents

49. Cerdelga patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7196205 GENZYME CORP Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Aug 19, 2021
New Chemical Entity Exclusivity(NCE) Aug 19, 2019
Orphan Drug Exclusivity(ODE-73) Aug 19, 2021

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

NCE-1 date: 19 August, 2018

Market Authorisation Date: 19 August, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's drug patent expiration?
More Information on Dosage

CERDELGA family patents

Family Patents

50. Chlorhexidine Gluconate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7427574 SAGE PRODS Non-woven wash cloth
Apr, 2026

(2 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: NA

Dosage: CLOTH;TOPICAL

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

Family Patents

51. Clindesse patents expiration

CLINDESSE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789057 PADAGIS US Pharmaceutical delivery system
Dec, 2026

(2 years from now)

Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Method of treating bacterial vaginosis

Dosage: CREAM;VAGINAL

How can I launch a generic of CLINDESSE before it's drug patent expiration?
More Information on Dosage

CLINDESSE family patents

Family Patents

52. Clorotekal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969412 B BRAUN MEDICAL INC Use for a composition comprising chloroprocaine HCL, a new composition comprising chloroprocaine HCL and a method for its manufacture
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 26, 2020

Drugs and Companies using CHLOROPROCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 September, 2017

Treatment: A method for inducing a regional anaesthesia via intrathecal administration of a patented preservative free solution for injection (with a specific composition, ph, osmolality and density) containing ...

Dosage: SOLUTION;INTRATHECAL

More Information on Dosage

CLOROTEKAL family patents

Family Patents

53. Colazal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

US7625884 VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jun 20, 2014
Orphan Drug Exclusivity(ODE) Dec 20, 2013

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 18 July, 2000

Treatment: Treatment of ulcerative colitis

Dosage: CAPSULE;ORAL

How can I launch a generic of COLAZAL before it's drug patent expiration?
More Information on Dosage

COLAZAL family patents

Family Patents

54. Combivent Respimat patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

55. Cometriq patents expiration

Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7579473 EXELIXIS c-Met modulators and methods of use
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-33) Nov 29, 2019
Orphan Drug Exclusivity(ODE) Nov 29, 2019
New Chemical Entity Exclusivity(NCE) Nov 29, 2017

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

NCE-1 date: 29 November, 2016

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

COMETRIQ family patents

Family Patents

56. Coreg Cr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209

(Pediatric)

WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Mar, 2026

(1 year, 10 months from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage

COREG CR family patents

Family Patents

57. Corlanor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-234) Apr 22, 2026
Pediatric Exclusivity(PED) Oct 22, 2026
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
New Product(NP) Apr 22, 2022

Drugs and Companies using IVABRADINE ingredient

NCE-1 date: 22 October, 2025

Market Authorisation Date: 22 April, 2019

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: SOLUTION;ORAL

More Information on Dosage

CORLANOR family patents

Family Patents

58. Corlanor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7361649 AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7361650 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7879842 AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Feb, 2026

(1 year, 10 months from now)

US7867996 AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361650

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7879842

(Pediatric)

AMGEN INC Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

US7361649

(Pediatric)

AMGEN INC β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 15, 2020
Pediatric Exclusivity(PED) Oct 15, 2020

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

NCE-1 date: 16 October, 2019

Market Authorisation Date: 15 April, 2015

Treatment: A method for treating heart failure in a human using a crystalline form of ivabradine hydrochloride

Dosage: TABLET;ORAL

How can I launch a generic of CORLANOR before it's drug patent expiration?
More Information on Dosage

CORLANOR family patents

Family Patents

59. Cotellic patents expiration

COTELLIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11597699 GENENTECH INC MEK inhibitors and methods of their use
Oct, 2026

(2 years from now)

US8362002 GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Oct, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-902) Oct 28, 2025
M(M-278) Jul 28, 2025
Orphan Drug Exclusivity(ODE-416) Oct 28, 2029
Pediatric Exclusivity(PED) Jan 28, 2026
Orphan Drug Exclusivity(ODE-101) Nov 10, 2022
New Chemical Entity Exclusivity(NCE) Nov 10, 2020
Orphan Drug Exclusivity(ODE) Nov 10, 2022

Drugs and Companies using COBIMETINIB FUMARATE ingredient

NCE-1 date: 28 January, 2025

Market Authorisation Date: 10 November, 2015

Treatment: As a single agent for the treatment of adult patients with histiocytic neoplasms; Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

More Information on Dosage

COTELLIC family patents

Family Patents

60. Cotempla Xr-odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840924 NEOS THERAPS INC Compositions and methods of making rapidly dissolving ionically masked formulations
Jun, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 19, 2020

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's drug patent expiration?
More Information on Dosage

COTEMPLA XR-ODT family patents

Family Patents

61. Cresemba patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6812238

(Pediatric)

ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
May, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-90) Mar 06, 2022
New Chemical Entity Exclusivity(NCE) Mar 06, 2020
Orphan Drug Exclusivity(ODE-305) Mar 06, 2022
Orphan Drug Exclusivity(ODE-453) Dec 08, 2030
New Patient Population(NPP) Dec 08, 2026
Orphan Drug Exclusivity(ODE-459) Dec 08, 2030
Pediatric Exclusivity(PED) Jun 08, 2031
Generating Antibiotic Incentives Now(GAIN) Sep 06, 2027
Orphan Drug Exclusivity(ODE) Mar 06, 2022

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 08 June, 2030

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS; CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

Family Patents

62. Dexilant patents expiration

DEXILANT's oppositions filed in EPO
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 8 months from now)

US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 8 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 10 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

US7790755 TAKEDA PHARMS USA Controlled release preparation
Aug, 2026

(2 years from now)

US8105626 TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 30, 2012
New Patient Population(NPP) Jul 08, 2019
Pediatric Exclusivity(PED) Jul 30, 2012

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage

DEXILANT family patents

Family Patents

63. Dexilant Solutab patents expiration

DEXILANT SOLUTAB's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238029 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 8 months from now)

US8461187 TAKEDA PHARMS USA Multiple PPI dosage form
Jan, 2026

(1 year, 8 months from now)

US9011926 TAKEDA PHARMS USA Method for producing granules
Feb, 2026

(1 year, 10 months from now)

US8461187

(Pediatric)

TAKEDA PHARMS USA Multiple PPI dosage form
Jul, 2026

(2 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 26 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

More Information on Dosage

DEXILANT SOLUTAB family patents

Family Patents

64. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8435502 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers
Sep, 2026

(2 years from now)

US8709392 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Mar 17, 2013

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 17 March, 2010

Treatment: Treatment of acne

Dosage: LOTION;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

65. Duexis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8449910 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(2 years from now)

US8501228 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(2 years from now)

US8067033 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(2 years from now)

US8067451 HORIZON Methods and medicaments for administration of ibuprofen
Jul, 2026

(2 years from now)

US8318202 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(2 years from now)

US8309127 HORIZON Stable compositions of famotidine and ibuprofen
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Apr 23, 2014

Drugs and Companies using FAMOTIDINE; IBUPROFEN ingredient

Market Authorisation Date: 23 April, 2011

Treatment: Relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for those indications

Dosage: TABLET;ORAL

How can I launch a generic of DUEXIS before it's drug patent expiration?
More Information on Dosage

DUEXIS family patents

Family Patents

66. Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441543 ABBVIE Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US9149428 ABBVIE Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: NA

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents

67. Dymista patents expiration

DYMISTA's oppositions filed in EPO
DYMISTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids
Feb, 2026

(1 year, 10 months from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Feb 20, 2018
Pediatric Exclusivity(PED) Aug 20, 2018
New Combination(NC) May 01, 2015

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 01 May, 2012

Treatment: NA

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage

DYMISTA family patents

Family Patents

68. Elepsia Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425938 TRIPOINT Pharmaceutical composition
Feb, 2026

(1 year, 10 months from now)

US8535717 TRIPOINT Pharmaceutical composition
Feb, 2026

(1 year, 10 months from now)

Drugs and Companies using LEVETIRACETAM ingredient

Market Authorisation Date: 20 December, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

ELEPSIA XR family patents

Family Patents

69. Eliquis patents expiration

ELIQUIS Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6967208 BRISTOL MYERS SQUIBB Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-690) Aug 21, 2017
New Indication(I-661) Aug 21, 2017
New Indication(I-691) Aug 21, 2017
New Indication(I-681) Mar 03, 2017
New Chemical Entity Exclusivity(NCE) Dec 28, 2017

Drugs and Companies using APIXABAN ingredient

NCE-1 date: 28 December, 2016

Market Authorisation Date: 28 December, 2012

Treatment: Prophylaxis of pulmonary embolism

Dosage: TABLET;ORAL

How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage

ELIQUIS family patents

Family Patents

70. Entresto patents expiration

ENTRESTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Nov, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-82) Feb 16, 2024
Pediatric Exclusivity(PED) Apr 01, 2023
New Chemical Entity Exclusivity(NCE) Jul 07, 2020
New Patient Population(NPP) Oct 01, 2022

Drugs and Companies using SACUBITRIL; VALSARTAN ingredient

NCE-1 date: 01 April, 2022

Market Authorisation Date: 07 July, 2015

Treatment: Treatment of heart failure

Dosage: TABLET;ORAL

How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage

ENTRESTO family patents

Family Patents

71. Epanova patents expiration

EPANOVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Dec, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2019

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

NCE-1 date: 05 May, 2018

Market Authorisation Date: 05 May, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

Family Patents

72. Esbriet patents expiration

ESBRIET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8753679 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7767225 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

US7988994 GENENTECH INC Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Sep, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021

Drugs and Companies using PIRFENIDONE ingredient

NCE-1 date: 15 October, 2018

Market Authorisation Date: 15 October, 2014

Treatment: Method of administering pirfenidone capsules to treat a fibrotic condition

Dosage: CAPSULE;ORAL

How can I launch a generic of ESBRIET before it's drug patent expiration?
More Information on Dosage

ESBRIET family patents

Family Patents

73. Evzio patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2026

(1 year, 9 months from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2026

(1 year, 11 months from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US11590286 KALEO INC Devices, systems and methods for medicament delivery
Dec, 2026

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO family patents

Family Patents

74. Evzio (autoinjector) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278182 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2026

(1 year, 9 months from now)

US8926594 KALEO INC Devices, systems and methods for medicament delivery
Mar, 2026

(1 year, 11 months from now)

US7731686 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US10960155 KALEO INC Devices, systems and methods for medicament delivery
Jun, 2026

(2 years from now)

US11590286 KALEO INC Devices, systems and methods for medicament delivery
Dec, 2026

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

EVZIO (AUTOINJECTOR) family patents

Family Patents

75. Farxiga patents expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

76. Fetzima patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43879 ABBVIE Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(1 year, 8 months from now)

Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Jul 25, 2018
M(M-249) Oct 07, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: Treatment of major depressive disorder (mdd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's drug patent expiration?
More Information on Dosage

FETZIMA family patents

Family Patents

77. Fiasp Flextouch patents expiration

FIASP FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 9 months from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 9 months from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 9 months from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 9 months from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 9 months from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 9 months from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 19, 2022
New Product(NP) Sep 29, 2020
M(M-247) Oct 21, 2022

Drugs and Companies using INSULIN ASPART ingredient

Market Authorisation Date: 29 September, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

FIASP FLEXTOUCH family patents

Family Patents

78. Flonase Sensimist Allergy Relief patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062264 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(1 year, 11 months from now)

US8752543 GLAXOSMITHKLINE CONS Fluid dispensing device
Apr, 2026

(1 year, 11 months from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 27 April, 2007

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

FLONASE SENSIMIST ALLERGY RELIEF family patents

Family Patents

79. Flovent Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7500444 GLAXO GRP LTD Actuation indicator for a dispensing device
Feb, 2026

(1 year, 10 months from now)

US7500444

(Pediatric)

GLAXO GRP LTD Actuation indicator for a dispensing device
Aug, 2026

(2 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 14 May, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of FLOVENT HFA before it's drug patent expiration?
More Information on Dosage

FLOVENT HFA family patents

Family Patents

80. Fycompa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8772497 CATALYST PHARMS Method for producing 1, 2-dihydropyridine-2-one compound
Jul, 2026

(2 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 22, 2017

Drugs and Companies using PERAMPANEL ingredient

NCE-1 date: 22 October, 2016

Market Authorisation Date: 29 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL; TABLET;ORAL

How can I launch a generic of FYCOMPA before it's drug patent expiration?
More Information on Dosage

FYCOMPA family patents

Family Patents